RxDoctor Payments Data

Udaya Swarna, MD

Clinical Cardiac Electrophysiology · Abilene, TXNPI 1306944962

Payments from drug & device makers

$23,974in general payments, 2019–2025

Across 365 payments — averaging $65.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$13K
  • Pfizer$5K
  • Medtronic$3K
  • AstraZeneca$692
  • Boston Scientific$647
  • Novartis$476
  • plus $2K from 15 others

What the payments were for

  • Consulting fees$1631%
  • Speaking & faculty fees$4,20018%
  • Travel & lodging$11,24547%
  • Food & beverage$8,25734%
  • Education$1090%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$23,974 in reported general payments places this provider in the 35th percentile of 233 clinical cardiac electrophysiology providers in Texas.

See all clinical cardiac electrophysiology providers in Texas

Medicare billing

Part B allowed, 2024
$502,622
Medicare patients
3,779
Services billed
8,763

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban903$850,874
XareltoRivaroxaban317$367,982
FarxigaDapagliflozin Propanediol297$277,134
EntrestoSacubitril/Valsartan242$267,506
Repatha SureclickEvolocumab128$82,547
BrilintaTicagrelor72$48,201
Praluent PenAlirocumab63$37,697
JardianceEmpagliflozin23$29,522
Metoprolol Succinate1,463$24,574
MultaqDronedarone Hcl21$15,506
Propafenone Hcl222$9,408
Sildenafil Citrate25$9,378
Rosuvastatin Calcium585$7,388
Amiodarone Hcl316$7,257
Dabigatran EtexilateDabigatran Etexilate Mesylate16$6,569

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$4,587$850,874903 claims
Johnson & JohnsonXarelto$392$367,982317 claims
AstraZenecaFarxiga, Brilinta$692$325,335369 claims
NovartisEntresto$476$267,506242 claims
Boehringer IngelheimJardiance$42$29,52223 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 233 clinical cardiac electrophysiology providers in Texas.

Other clinical cardiac electrophysiology in Abilene

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →